1515 Holcombe Blvd.
Unit Number: 1202
Houston, TX 77030
Room Number: ACB P1.2864
Abstract
Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells. 2002 FDA approved Ibritumomab tiuxetan (Zevalin) as RIT in treatment of refractory non-Hodgkins lymphoma. Further, in June 14, 2014 FDA restricted approval Zevalin in MD Anderson center as treatment of aging inoperable and non-responsiveness bladder cancer to usual chemo-radiotherapy. The purpose of this study is to comparative RIT aspects as first line treatment in the aging group bladder cancer to traditional chemotherapy or radiotherapy regimen. A non-randomized, prospective, comparative, single-study conducted included all old patients with refractory bladder cancer. Of the 51 patients enrolled, median age was 79.7 years and overall response rate was 75% vs. 23% , 25% in 2nd dose chemotherapy and radiotherapy respectively. All patient with RIT were CR, further, patients who had received one prior chemotherapeutic regimens had a higher response than those who had received more than two prior regimens (67% vs. 11%, P<0.001).
Keywords: Radioimmunotherapy; Ibritumomab; A non-randomized; Refractory bladder cancer
References
1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8–29. [PubMed]
2. Press OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologists. Semin Oncol 2000;27:62–73. [PubMed]
3. Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, and Casadevall A. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc Natl Acad Sci USA 2004;101: 14865-70.
4. Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004;48(4):289-96.
5. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9(16 Pt 1):5842-52.
6. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int J Radiat Oncol Biol Phys. 2004;58(3):972-5.
7. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP, Moon S, Scott P, Miller RA, Wahl RL. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696–1711. [Abstract/FREE Full Text]
8. Liu PF, Cao YW, Jiang HP, Wang YH, Yang XC, Wang XS, Niu HT. Heterogeneity research in muscle-invasive bladder cancer based on differential protein expression analysis. Med Oncol. 2014; 31(9):21. [PubMed]
9. Niu HT, Qi XJ, Liu YQ, Cao YW, Dong Q, Wang XS. Parallel proteomic analysis in muscle-invasive bladder transitional cell carcinoma and cancer-related stroma. Genet Mol Res. 2013 ;12(4):4251-63. [PubMed]
10. van Rhijn BW. Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer. Urol Oncol 2012; 30: 518–523. [PubMed]
11. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol 2012; 6: 251–259.
12. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011; 364: 1144–1153. [PubMed]
13. Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, et al. Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. Cancer Prev Res (Phila) 2010; 3: 1235–1245. [PubMed]
14. Chang DW, Gu J, Wu X. Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. Urol Oncol 2012; 30: 524–532. [PubMed]
15. Gu J, Wu X. Genetic susceptibility to bladder cancer risk and outcome. Per Med 2011; 8: 365–374. [PubMed]
16. Rafnar T, Vermeulen SH, Sulem P, Thorleifsson G, Aben KK, et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet 2011; 20: 4268–4281. [PubMed]
17. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010; 42: 415–419. [PubMed]
18. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 2008; 40: 1307–1312. [PubMed]
19. Fu YP, Kohaar I, Rothman N, Earl J, Figueroa JD, et al. Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk. Proc Natl Acad Sci USA 2012; 109: 4974–4979. [PubMed]
20. Cortessis VK, Yuan JM, Van Den Berg D, Jiang X, Gago-Dominguez M, et al. Risk of urinary bladder cancer is associated with 8q24 variant rs9642880[T] in multiple racial/ethnic groups: results from the Los Angeles-Shanghai case-control study. Cancer Epidemiol Biomarkers Prev 2010;19: 3150–3156. [PubMed]
21. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. Eur Urol 2013; 64: 639–653. [PubMed]
